GSK Removes Blenrep From U.S. Market, Due Poor Clinical Trial Performance for Multiple Myeloma Drug
The multiple myeloma drug Blenrep is being removed from the U.S. market after the fast-tracked cancer drug failed to perform in a recent clinical trial.